Emerging Novel Functional Imaging and Immunotherapy in Renal Cell Carcinoma and Current Treatment Sequencing Strategies After Immunotherapy
Details
Publication Year 2024-06,Volume 44,Issue #3,Page e438658
Journal Title
American Society of Clinical Oncology Educational Book
Publication Type
Review
Abstract
The management of renal cell carcinoma (RCC) has advanced significantly in the past two decades. Many promising functional imaging modalities such as radiolabeled tracer targeting carbonic anhydrase IX and prostate-specific membrane antigen are under development to detect primary kidney tumors, stage systemic disease, and assess treatment response in RCC. Immune checkpoint inhibitors targeting PD-1 and cytotoxic T-cell lymphocyte-4 have changed the treatment paradigm in advanced RCC. Trials investigating novel mechanisms such as LAG-3 immune checkpoint inhibition, chimeric antigen receptor T-cell therapies, and T-cell engagers targeting RCC-associated antigens are currently ongoing. With the rapidly changing treatment landscape of RCC, the treatment sequence strategies will continue to evolve. Familiarity with the toxicities associated with the therapeutic agents and how to manage them are essential to achieve optimal patient outcomes. This review summarizes the recent developments of functional imaging and immunotherapy strategies in RCC, and the evidence supports treatment sequencing.
Publisher
American Society of Clinical Oncology
Keywords
Humans; *Carcinoma, Renal Cell/therapy; *Immunotherapy/methods; *Kidney Neoplasms/therapy; Immune Checkpoint Inhibitors/therapeutic use
Department(s)
Radiation Oncology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-30 06:26:11
Last Modified: 2024-07-30 06:34:07

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙